Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

8.7%

2 terminated out of 23 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

36%

5 of 14 completed with results

Key Signals

5 with results88% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (7)
P 1 (5)
P 2 (6)
P 4 (3)

Trial Status

Completed14
Withdrawn2
Terminated2
Recruiting2
Unknown1
Active Not Recruiting1

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07340554Not ApplicableRecruiting

Neuroimaging of Adolescent Cannabis Use Treatment

NCT07523633Phase 2Not Yet Recruiting

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

NCT06395688Phase 1WithdrawnPrimary

Drug-Drug Interaction Between THC and AEF0117

NCT07091292Not ApplicableRecruitingPrimary

Exercise Intervention as Treatment for People Using Cannabis (ExIT-C)

NCT05833230Not ApplicableCompleted

Investigating Real-world Stress-related Mechanisms in Heavy Cannabis Users

NCT06249542Not ApplicableCompleted

Implementing Screening for Cannabis and Other Drug Use Disorders in Primary Care: Impact on Diagnosis and Treatment

NCT05219825Not ApplicableActive Not Recruiting

Breathwork-assisted Treatment for Cannabis Use Disorder

NCT01439828Phase 2Terminated

Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal

NCT01110434Phase 2CompletedPrimary

Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents

NCT01639872Phase 4Completed

Clozapine for Cannabis Use in Schizophrenia

NCT02319746Not ApplicableCompleted

COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE

NCT00498550Phase 4Completed

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

NCT01603992CompletedPrimary

Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms

NCT01037608Phase 1Completed

Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation

NCT01784627Phase 1Withdrawn

Trial of Computerized SBI to Reduce Teen Alcohol Use

NCT01875796Phase 1Completed

Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders

NCT00149643Phase 2Completed

Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence

NCT01204723Phase 1Completed

Medications Development for the Treatment of Cannabis Related Disorders

NCT00484367Phase 2Unknown

A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers

NCT00687609Phase 4Terminated

Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

Scroll to load more

Research Network

Activity Timeline